Patent ID: 11970553
Assignee: BICYCLETX LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating cancer in a patient, comprising administering to the patient a heterotandem bicyclic peptide complex comprising:
(a) a first peptide ligand, which binds to Nectin-4 and which comprises the sequence CiP[1Nal][dD]CiiM[HArg]DWSTP[HyP]WCiii (SEQ ID NO: 1); conjugated via an N-(acid-PEG3)-N-bis(PEG3-azide) linker to
(b) two second peptide ligands, each of which binds to CD137 and each of which comprises the sequence Ac-Ci[tBuAla]PE[D-Lys(PYA)]PYCiiFADPY[Nle]Ciii-A (SEQ ID NO: 2);
or a pharmaceutically acceptable salt thereof,
wherein Ci, Cii and Ciii of SEQ ID NOs: 1 and 2 each form covalent bonds with a molecular scaffold comprising 1,1′,1″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA) thereby forming two polypeptide loops for each of SEQ ID NOs: 1 and 2; and
wherein Ac represents acetyl, HArg represents homoarginine, HyP represents trans-4-hydroxy-L-proline, 1Nal represents 1-naphthylalanine, tBuAla represents t-butyl-alanine, PYA represents 4-pentynoic acid and Nle represents norleucine.